Please sign in to follow a disease.
Synovial sarcoma
MONDO:0010434Synovial sarcoma is an aggressive soft tissue sarcoma, occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).
Also known as: SS, Synovialosarcoma, sarcoma, synovial, malignant, synovial sarcoma, synovial sarcoma (disease), sarcoma, synovial
2863 clinical trials for this condition and its sub-types, 53 tagged with Synovial sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Synovial sarcoma
-
Biphasic synovial sarcoma 0 trials
-
Breast synovial sarcoma 0 trials
-
Fibrous synovial sarcoma 0 trials
-
Mediastinum synovial sarcoma 0 trials
-
Monophasic synovial sarcoma 0 trials
2 sub-types
- Epithelioid cell synovial sarcoma 0 trials
- Spindle cell synovial sarcoma 0 trials
-
New immunotherapy targets rare cancers by harnessing the Body's immune system
Disease control Not yet recruitingThis phase 2 trial tests a new drug called brenetafusp (IMC-F106C) in people with rare cancers—synovial sarcoma and myxoid liposarcoma—that have spread or cannot be surgically removed. The drug is a type of immunotherapy designed to guide the body's immune cells to attack cancer …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental combo aims to tackle Treatment-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC